他扎罗汀对寻常型银屑病患者血清TNF-α及VEGF水平的影响被引量：7

Effects of topical Tazarotene on serum level of TNF-α and VEGF in patients with psoriasis vulgaris

下载PDF

导出

摘要目的研究外用他扎罗汀对银屑病患者血清肿瘤坏死因子-α(TNF-α)和血管内皮生长因子(VEGF)的调节作用,探讨他扎罗汀治疗银屑病的机制。方法应用双抗体夹心酶联免疫吸附法(ELISA)检测34例银屑病患者经他扎罗汀治疗前、后外周血清中TNF-α和VEGF水平。结果银屑病患者他扎罗汀治疗前的血清TNF-α、VEGF水平均高于治疗后(P<0.01)及对照组(P<0.01)。治疗前、后血清TNF-α、VEGF水平与PASI分值均呈显著线性正相关。结论他扎罗汀通过下调TNF-α和VEGF的表达,从而抑制皮损处的炎症反应和血管生成,可能是其治疗银屑病的机制之一。 Objective To investigate the regulating action of tazarotene on TNF-α and VEGF in psoriasis and its mechanism in the treatment of psoriasis.Methods Serum level of TNF-α and VEGF was measured by double antibody sandwich enzyme-linked immunosorbent assay（ELISA）before and after treatment with tazarotene in 34 patients with psoriasis vulgais.Results The serum levels of TNF-α and VEGF before treatment with tazarotene was significantly higher than that after treatment（P0.01）and in normal controls（P0.01）.The serum level of TNF-α and VEGF before and after treatment had a significantly linear positive correlation with PASI scores.Conclusion It might be one of the mechanisms of tazarotene on topical treatment of psoriasis that Tazarotene inhibites inflammatory reaction and angiogenesis via down-regulating the expression of TNF-α and VEGF in psoriasis.

作者丁小洁陈燕熊心猜于春水徐国林邓利丽

机构地区川北医学院附属医院皮肤科

出处《重庆医学》 CAS CSCD 北大核心 2010年第19期2638-2639,共2页 Chongqing medicine

关键词他扎罗汀寻常型银屑病肿瘤坏死因子-Α 血管内皮生长因子 tazarotene psoriasis vulgaris tumor necrosis factor-α vascular endothelial growth factor

分类号 R758.63 [医药卫生—皮肤病学与性病学]

引文网络
相关文献

参考文献6

1Linden KG,Weinstein GD.Psoriasis:current perspectives with an emphasis on treatment[J].Arch Dermatol,1999,107(6):595.
2韩钢文,俞宝田,李惠,朱学骏,王宝玺,李桂明,杨海珍,何志新,何晓琴,王丹,马东来,陈家秀,谢勇.他扎罗汀凝胶与钙泊三醇软膏随机对照治疗寻常性斑块型银屑病多中心临床试验[J].中国临床药理学杂志,2001,17(6):419-422. 被引量：17
3Datmer M,Brown LF,Claffey KP,et al.Overexpresion of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis[J].J Exp Med,1994,180(3):1141.
4Xia YP,Li B,Hylton D,et al.Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis[J].Blood,2003,102(1):161.
5张宪旗,冯捷,李建国,徐汉卿,汤成利,曹振平,张磐谏.他扎罗汀抑制角质形成细胞血管内皮生长因子的表达[J].中国皮肤性病学杂志,2003,17(3):162-163. 被引量：4
6张洁,刁庆春,闫国富,朱小娟.他扎罗汀乳膏治疗寻常型斑块性银屑病的疗效和安全性观察[J].重庆医学,2008,37(12):1293-1294. 被引量：7

二级参考文献13

1刘红华,单筠筠.他扎罗汀凝胶及地塞米松霜治疗寻常型银屑病[J].中国药师,2006,9(11):1039-1039. 被引量：3
2[1]Chandraratna RAS.Tazarotene-first of a new generation of receptor-selective retinoids. Br J Dermatol, 1996;135(Supp.149):18～25.
3[2]Weinstein G, Jeffes E,et al.Tazarotene gel for the treatment of plaque psoriasis: a double-blind clinical study. J Invest Dermatol,1995;104:661.
4[3]Marks R: Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol, 1997;37:S25～S32.
5Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment [ J ]. Arch Dermatol, 1998,134 : 57 - 60.
6Bhushan M, Mclaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating anglogenesis factor and vascular endothelial growth factor are elevated in psoriasis[J]. Br J Dermatol, 1999, 141(6): 1054 -1060.
7Detmar M,Brown LF,Borse B, et al. Hypoxia regulates the expression vascular permeability factor/vascular endothelial growth factor(VPF/VEGF) and its receptors in human skin[J ]. J Invest Dermatol, 1997,108 : 263-268.
8Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/Vascular endothelial growth facter, microvascular hyperpermeability and angiogenesis[ J ]. Am J Pathol, 1995,146(5) : 1029 - 1039.
9Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability facter/vascular endothelial growth factor and its receptors in psoriasis[ J ]. J Exp Med, 1994,180:1141 - 1146.
10Elder JT, Fisher GT, Lindquist PB, et al. Overexpression of transforming growth factor alpha in psoriatic epidermis[J]. Science, 1989,243:811-814.